U.S. stock night trading fluctuations: Scinai Immunotherapeutics surged 20.17% in night trading, with active capital flow attracting market attention

U.S. Stock Night Market Movements Scinai Immunotherapeutics rose 20.17% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry BeiGene fell 1.92% in the night market. Based on recent key news: On December 15, BeiGene recorded a large cross-trade, with the stock price down 6.9% compared to the previous closing price, leading to a decline in stock price. This transaction involved an amount of 32.63 million yuan, indicating increased selling pressure on the stock, affecting its price downward. On December 15, the market capitalization of innovative pharmaceutical companies in the global healthcare industry significantly increased, and BeiGene, as one of the innovative pharmaceutical companies, has attracted attention regarding its market position. Although it performs strongly in the U.S. market, its revenue in the domestic market is relatively low, affecting investor confidence. On December 15, the reform of the healthcare service industry has not been effectively advanced, leading to uneven distribution of medical resources and affecting the overall industry development. As part of the pharmaceutical industry, BeiGene's stock price is influenced by macro policies. The increase in market capitalization of innovative pharmaceutical companies accelerates industry transformation. Recursion Pharmaceuticals fell 2.38% in the night market, with a trading volume of $755,000, and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Radiopharm Theranostics fell 42.24% in the night market. Based on recent key news: On December 15, Radiopharm Theranostics achieved a 92% primary endpoint achievement rate in the Phase 2B imaging trial of RAD 101, showing significant tumor uptake and FDA fast track designation. This result improved diagnostic accuracy, driving the stock price up 292.72% in pre-market trading. Source: Benzinga On December 15, Radiopharm Theranostics announced that its RAD 402 received approval in Australia for the first human clinical trial for the treatment of prostate cancer. This progress led to a 141.31% increase in the company's stock price on that day. Source: Benzinga On December 15, the CEO of Radiopharm Theranostics stated that RAD 101 combined with standard MRI has the potential to change patient management, with expected market opportunities in the U.S. exceeding $500 million. This optimistic outlook drove a short-term increase in stock price. Source: Benzinga The biotechnology industry has recently experienced significant volatility, and investment should be approached with caution